Best Competitive Intelligence Platforms for Pharma BD in 2026
Maven Bio provides live intelligence that keeps BD assessments current with source-linked edits to selected working files.1 For example, Maven Bio maintains the evidence behind a licensing assessment,1 Cortellis Deals Intelligence organizes transaction terms and available contracts,2 and BioCentury BCIQ connects company, product, financing, and deal research.3
The best CI platforms for pharma BD teams support a specific decision about an asset, a transaction, or a potential partner. This guide covers licensing-candidate screening, deal and financing comparables, asset diligence, and partner landscapes. It compares six platforms by the evidence and outputs used in those decisions. The question is how the research contributes to a BD work product, from an initial opportunity screen to a maintained assessment of the case for proceeding.
For a broader view of research and writing workflows, see AI platforms for biopharma business development. For ongoing competitor monitoring across functions, see pharma competitive intelligence platforms. This comparison stays with BD evidence, including what makes a transaction comparable and what distinguishes a plausible partner from a company that merely appears in the same landscape.
Clarivate's life-sciences business now identifies itself as Insira. Cortellis remains a named product in that portfolio, and this guide retains Cortellis Deals Intelligence as the product being compared.4

Jump to a platform
How we assessed these platforms
We reviewed product pages, help guides, integration documentation, and pricing pages on November 19, 2026. The assessment follows the research needed to identify an opportunity, understand the relevant evidence, and communicate a BD judgment. Maven Bio publishes this guide, and its own entry is held to the same evidence standard, with every claim linked to a public page.
| Criterion | What we checked |
|---|---|
| Licensing screens | Asset, company, stage, target, indication, and mechanism context for defining a candidate set |
| Deal comparables | Transaction structure, territories, development stage, payment terms, and available contracts |
| Financing context | Company financing activity and its connection to partner or asset research |
| Diligence evidence | Sources supporting scientific, development, and commercial assumptions |
| Partner landscapes | Company pipelines, historical transactions, and connected company information |
| Research delivery | Tables, exports, maintained files, and the treatment of later changes |
| Connected access | MCP, APIs, and available data-delivery routes |
The guide does not give an overall score. The entries cover different parts of a BD workflow. A forecast dataset, a transaction database, and a maintained diligence assessment are different research inputs. Their value follows the question they resolve, rather than the number of fields or the length of a generated report.
BD research tasks compared
The table compares deal and financing records with working-file updates and connected access. The final column concerns a provider's own consensus sales forecast dataset.
| Platform | Deal records | Financing records | Source-linked edits to working files with rollback | MCP connection | API access | Provider consensus sales forecast dataset |
|---|---|---|---|---|---|---|
| Maven Bio8 | Yes | Yes | Yes | Yes | Yes | No |
| Cortellis Deals Intelligence2 | Yes | Not described | Not described | Not described | Yes | Not described |
| DealForma5 | Yes | Yes | Not described | Not described | Yes | Not described |
| BioCentury BCIQ3 | Yes | Yes | Not described | Not described | Not described | Not described |
| Evaluate6 | Yes | Yes | Not described | Yes | Yes | Yes |
| Citeline Pharmaprojects+7 | Not described | Not described | Not described | Not described | Yes | Not described |
Not described means the provider's public pages do not document it.
Prices on record
The public pages below were checked on November 19, 2026. Dollar amounts are USD. Quote only means no monetary price is published for the named offer on the reviewed page. A separately named product or dataset does not become included because the same provider sells it.
| Platform | Public offer on record |
|---|---|
| Maven Bio | Quote only for annual team plans9 |
| Cortellis Deals Intelligence | Quote only on the product page2 |
| DealForma | $18,000 annually for one user, $32,000 annually for two users, and group or enterprise pricing quoted for three or more users10 |
| BioCentury BCIQ | Quote only through the subscription request page11 |
| Evaluate | Tailored package pricing quoted, with Ask Ella included where the subscription provides it1213 |
| Citeline Pharmaprojects+ | Quote only for a package matched to use case and access needs7 |
Maven Bio
Best for
BD teams that need the evidence behind an opportunity to stay connected to the assessment used in decisions.
Maven Bio provides live intelligence that monitors developments against a team's priorities and applies source-linked edits to selected Word, Excel, and PowerPoint files, with revision history and rollback.1 Research Agent supports direct answers, reviewable research plans, and finished deliverables through Answer, Plan, and Work modes, with supporting passages attached to claims.14 Teams can supply assessment criteria, project context, source preferences, and document templates, then save the method and format as a workflow that runs on demand or on a schedule.815
Smart Tables applies research columns across drugs, companies, or trials filtered by indication, mechanism, stage, and other structured fields; each cell can show supporting quotes, evidence ratings, and research steps.16 Document Grids extracts common fields across publications, abstracts, and diligence materials, including populations, endpoints, comparators, follow-up, and missing details, with supporting passages retained beside the findings.17 The read-only MCP connector supplies research access inside a compatible assistant, while the API retrieves structured biopharma data and monitoring findings and webhooks notify connected systems of new signals.8
Coverage
Maven Bio covers 100,000+ drug products, 30,000+ companies, and 11 source classes worldwide.8
Price on record
Maven Bio's annual team plans are quote only. Pooled AI credits and scope reflect research volume, data rights, and integration needs.9
Pros
Source-linked edits keep selected working files current with revision history and rollback,1 while reusable workflows retain the team's research instructions and deliverable format.15
Cons
Maven Bio does not provide its own consensus sales forecast dataset.18
Cortellis Deals Intelligence
Best for
BD teams comparing transaction structures, payment terms, and available contract evidence.
Cortellis Deals Intelligence covers licensing, partnering, and M&A activity through deal terms, asset and company context, and available contracts.2 Users can create and export transaction analyses and financial summaries, inspect early-stage agreements, and review a prospective partner's transaction history.2 The product also describes predictive analytics for potential deal sizes and development progression, with the scope defined by indication, company, phase, and deal type.2
The Deals Intelligence API identifies parties, territories, indications, technologies, and the drug's highest phase both currently and when the agreement began.19 Its financial tables distinguish projected amounts at signing, current projections, and payments already made, including milestones, equity, upfront consideration, and royalties; dated events retain their associated drugs and payments.19 Exports can contain complete selected records or finance-focused summaries in Excel, with contracts retrievable where available.19 Consensus forecasts belong to the separately documented Cortellis CCI product and its MCP service, which also retrieves pipeline, company, and deal information.20
Coverage
The published collection contains 135,000+ deals, 37,000+ early-stage deals, 15,500+ deals with contracts, including 9,600 unredacted agreements, and 10,000+ M&A deals.2
Price on record
The product page does not publish a monetary subscription price. Cortellis Deals Intelligence is quote only.2
Pros
Deal records distinguish projected payments from amounts already paid,19 while available contract text and financial exports support examination of the terms behind transaction comparables.2
Cons
Contracts are available for only part of the deal collection. Contract availability therefore remains a deal-level constraint, including whether an unredacted agreement is supplied.2
DealForma
Best for
Teams whose BD research centers on licensing activity, financing transactions, and comparable deal structures.
DealForma connects deal, funding, company, and pipeline research, including financial terms, detailed transaction overviews, contracts, and supporting releases.5 The deal taxonomy covers licensing, R&D collaborations, academic agreements, M&A, spin-outs, and asset purchases, with fields for development stage, modality, indication, target, and territory.5 Funding coverage includes venture rounds, IPOs, follow-on offerings, investor histories, and financing details, while company profiles extend across biotech, pharma, diagnostics, medtech, digital therapeutics, and investment firms.5
The pipeline and sales collection includes early-stage compounds, platforms, branded drugs, labels, drug sales, launches, clinical trials, regulatory information, routes, dosages, and formulations.5 Natural-language search works alongside detailed filters, and common identifiers support connections to the team's other datasets.5 Tableau dashboards provide filtered views by therapy area, modality, stage, and other criteria; chart images and underlying data can be downloaded, and those dashboards refresh daily.21 The platform also describes API delivery into internal dashboards and exports for further analysis.5
Coverage
The published scope spans four collections, deals, funding, companies, and drug pipelines with sales data, with company coverage described as thousands of biopharma organizations.5
Price on record
DealForma publishes $18,000 annually for one user and $32,000 annually for two users. Group and enterprise offers for three or more users are quoted.10
Pros
Transaction and financing records connect deal terms with company activity,5 while filtered Tableau dashboards provide downloadable charts and data for further analysis and presentations.21
Cons
Tableau dashboards refresh daily, so their charts do not provide a continuously refreshed intraday view of transaction activity.21
BioCentury BCIQ
Best for
BD research that connects company profiles, development programs, financing history, and deal activity.
BCIQ integrates Companies, Products, Finance, and Deals modules, with research paths for indication landscapes, compounds by target, corporate financials, fundraising, and transaction activity.3 Teams can build and save peer groups around therapeutic categories and receive daily updates, while the Companies module supports reports about partners, potential collaborators, and competitors.3 The Products module supports discovery of licensing and investment opportunities, and Finance and Deals provide the associated capital and transaction records.3
The subscription page describes structured asset and company profiles, program filters by stage, modality, or mechanism, and deal comparisons across selected transactions.11 Company research combines financial information, pipelines, partners, and historical context, with saved screens and export into the team's models.11 BCIQ's export guide distinguishes chart images from the underlying data; the data can be sent to Excel for additional analysis, while the guide recommends screenshots when the chart itself is needed.22
Coverage
BioCentury lists 20,000+ programs tracked globally.11 Its BCIQ overview identifies four integrated modules and more than $1 trillion in financing coverage.3
Price on record
BioCentury requests subscription details through its public subscription page without displaying a monetary BCIQ price. BCIQ is quote only on that page.11
Pros
Integrated modules connect development programs with company, financing, and deal information,3 while saved peer groups and daily updates support recurring research on selected companies.3
Cons
BCIQ's export guide states that chart visuals cannot be exported. The underlying data can be exported to Excel, while the guide suggests a screenshot for the chart itself.22
Evaluate
Best for
Commercial assessment of a licensing candidate using consensus forecasts and related product or company information.
Evaluate Pharma combines consensus sales forecasts with product, pipeline, and company information, including worldwide and US indication-level sales coverage.6 Historical forecasts support examination of changing expectations, and the product identifies forecast outliers over time.6 Its commercial context also includes company and product deals, venture financing, IPO information, patent-expiration dates, sales at risk, and future development or regulatory events.6
Ask Ella answers questions from the licensed Evaluate records, links back to those sources, and retains the context of follow-up questions.13 The assistant is available within the named products supported by the subscription, rather than searching unrestricted public web material.13 Evaluate's delivery options include Snowflake, structured flat-file feeds, selected APIs, and MCP integrations; available routes depend on the dataset and intended workflow.23 Flat-file delivery supports CSV and XML, with format availability depending on the dataset and delivery requirements.23
Coverage
Evaluate Pharma lists forecasts for almost 6,000 drugs, indication-level worldwide sales for 5,000 drugs, and US indication sales for 2,500 drugs.6 Its historical collection includes 1.5 million+ consensus forecasts for 10,000 products dating to 2003.6
Price on record
Evaluate offers tailored package pricing based on the organization, data, users, and workflows. Ask Ella is included where the existing Evaluate subscription provides it, rather than being presented as a separate quoted platform.1213
Pros
Consensus forecasts supply a defined commercial reference for asset research,6 while Ask Ella links its answers to the licensed records supporting each response.13
Cons
Ask Ella answers from licensed Evaluate data and does not search the web. Public evidence outside that collection requires a separate research path.13
Citeline Pharmaprojects+
Best for
Licensing screens and asset comparisons organized around the global development pipeline.
Pharmaprojects+ follows development from preclinical research to launch and retains failed and withdrawn programs.7 Company Compare places active pipelines side by side, while Drug Similarity finds chemical, biologic, and mechanistic comparators.7 Search filters cover stage, modality, geography, mechanisms, and targets, and rare-disease records include orphan designations, development status, and sponsors.7 Dashboards show pipeline composition, phase progression, discontinuation patterns, and launch timelines, with annual snapshots supporting historical comparisons.7
Ella constructs and validates searches, returns structured answers from Pharmaprojects+ data, and links results to the source records.7 The assistant also works across Trialtrove+ and Sitetrove+, carrying the research context into related trial and site questions.7 Citeline's separate informatics offering provides drug, company, trial, investigator, and site data through APIs, including historical pipeline information and analytics for connected systems.24 Scheduled CSV or Parquet exports can be delivered through SFTP or cloud storage as full snapshots or daily change files, and Snowflake data shares are also available.24
Coverage
Citeline publishes 100,000+ drug profiles, 58,000+ data sources, and 40+ years of development history, with annual snapshots since 1995.7 Its stated scope includes 3,700+ mechanisms, 1,100+ targets, and 750+ rare diseases.7
Price on record
The Pharmaprojects+ page offers packages matched to use case and access needs without a monetary list price. The product is quote only.7
Pros
Failed and withdrawn programs remain available beside active assets,7 while company comparisons and drug similarity searches provide distinct ways to define a licensing landscape.7
Cons
The documented historical trend feature uses annual snapshots. That historical series does not provide a dated snapshot for every day between annual observations, even though current records are continuously updated.7
How to choose
Start with the BD decision. Licensing screens need a defensible candidate set. Deal comparables need transaction structure and timing. Asset diligence needs evidence behind scientific and commercial assumptions. Partner landscapes need company context and a clear distinction between observed history and inferred fit. A platform that resolves one of those questions can still leave the others to a separate research process.
Next, define the work product. A transaction table, an asset assessment, and a partner presentation have different review requirements. The table must preserve the comparability criteria. The assessment must distinguish facts, assumptions, and unresolved questions. The presentation must communicate the reasoning without losing the evidence behind the conclusion. Maven Bio's live intelligence connects later developments to selected working files,1 while the other entries document their own database, export, or research handoffs.
Finally, treat changes as part of the BD process. New clinical evidence, financing activity, or a revised development timeline can alter the interpretation of an opportunity. A research process should make clear which part of the case changed and which assumptions remain intact. The strongest fit is the platform or combination that supports the actual sequence of decisions, with the source evidence and the final work product remaining connected throughout.
Frequently asked questions
Which platform can screen licensing candidates against our own criteria?
Maven Bio's Smart Tables filters candidate records and applies the team's research questions as consistent columns, with evidence and open questions attached to each answer.16 Citeline Pharmaprojects+ provides company comparisons and chemical, biologic, and mechanistic similarity searches.7 The relevant distinction is between researching a team's assessment criteria across candidates and finding comparable assets through the database's structured search dimensions.
Why is headline deal value insufficient for a comparable?
A headline can combine payments with different timing and conditions. Upfront consideration, development milestones, commercial milestones, equity, and royalties are different economic components. Cortellis's API documentation distinguishes financial events and projected or paid amounts.19 A useful comparison keeps those components visible alongside stage and territory, so the transaction is not reduced to a single number detached from its structure.
How does financing research contribute to partner assessment?
Financing research supplies company context. It can help explain the sequence of capital raises and development activity around a potential partner. BCIQ's integrated modules and DealForma's funding coverage provide routes into that research.35 The resulting evidence supports a view of the company's history, while a claim about its current partnering intentions requires additional evidence rather than an assumption based on financing alone.
Which platforms help maintain the BD work product?
Maven Bio documents source-linked updates to selected Word, Excel, and PowerPoint files, with revision history and rollback.1 The other entries document database views, sourced responses, or exports within their named products. Those outputs can all contribute to a BD assessment, but the process for keeping the final assessment current is a separate part of the workflow.
Is a consensus sales forecast the same as an asset valuation?
No. A sales forecast describes expected commercial performance under a particular dataset or model. An asset valuation also reflects development risk, timing, costs, rights, and the proposed transaction. The forecast can be an input without being the conclusion. Keeping that distinction explicit makes it easier to explain why two teams can use similar market expectations and still reach different views of an opportunity.
Which platform combines partner research with financing and deal history?
Maven Bio links company, drug, deal, and financing evidence in its biopharma research environment.8 BioCentury BCIQ connects Companies, Products, Finance, and Deals modules, while DealForma covers licensing transactions and funding rounds with company context.35 Compare the transaction fields and company history each product supplies against the evidence your partner assessment needs.
Can BCIQ export the records behind a deal or financing chart?
BCIQ exports chart data to Excel, with a choice between the summarized values shown in the visual and the underlying records, including data points the chart does not display.22 Its table view also lets users adjust filters and columns before exporting. The chart artwork itself requires a screenshot or separate capture.22